Title : The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.

Pub. Date : 2021 Jun 8

PMID : 34103652






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Among them, the median progression-free survival (PFS) of first-line EGFR-TKI (PFS1) was 14.0 months, and the median PFS of osimertinib (PFS2) was 10.1 months. osimertinib GINS complex subunit 2 Homo sapiens